Understanding the Market | LaiKai Pharmaceuticals-B Surges Over 9% Again as New Obesity Treatment Drug Receives FDA Approval for Clinical Trials
Lai Kai Medicine-B rose by over 9% in the morning session, reaching a 9.51% increase to HKD 7.14 by the time of publication, with a trading volume of HKD 6.0072 million. On the news front, Lai Kai Medicine announced that its independently developed LAE102 (ActRIIA monoclonal antibody) has received approval from the U.S. Food and Drug Administration (FDA) for a new drug clinical trial (IND) for the treatment of obese patients. Huachuang Securities previously pointed out that the globally pioneering ActRIIA monoclonal antibody LAE102 can increase muscle mass and reduce fat, has the potential to be used in combination with GLP-1RA, has huge market potential, and possesses international value
According to the Wise Finance APP, Lai Kai Medicine-B (02105) surged over 9% in the morning session, with a 9.51% increase to HKD 7.14 as of the time of publication, with a turnover of HKD 6.0072 million.
On the news front, Lai Kai Medicine announced that its independently developed LAE102 (ActRIIA monoclonal antibody) has received approval from the U.S. Food and Drug Administration (FDA) for a new drug clinical trial (IND) to treat obese patients. Huachuang Securities previously pointed out that the globally pioneering ActRIIA monoclonal antibody LAE102 can increase muscle and reduce fat, has the potential to be used in combination with GLP-1RA, has huge market potential, and has international value